400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Financial Results, Press Release
Other Events
Investor Presentation
Retention Compensation Approved for Executive Officers at Tvardi Therapeutics
Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Announces Second Quarter 2025 Results and Provides Business Update
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities
S-1
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Post-Effective Amendment
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership